申请人:WANG HSIN-ELL
公开号:US20120178919A1
公开(公告)日:2012-07-12
A radiolabeled nucleoside analogue is provided, which includes radioactive iodine
123
I/
131
I, and a nucleoside analogue selected from a group consisting of cytidine, thymidine, uridine, and a derivative thereof. A method for preparing the radiolabeled nucleoside analogue, and a use thereof are further provided. The nucleoside analogue, prepared through the preparation method with a short synthesis time and a high radiochemical yield, has a long in vivo physiological half life and a high stability in serum, and, as a radiopharmaceutical composition, is useful in development of tumor proliferation diagnosis or therapy prognosis evaluation, and further assists in observation of long-time in vivo metabolism of a drug.
提供了一种放射性标记的核苷类似物,包括放射性碘123I/131I,以及从胞嘧啶、胸苷、尿苷和其衍生物组成的一组中选择的核苷类似物。还提供了一种制备放射性标记的核苷类似物的方法以及其用途。通过具有短合成时间和高放射化学产率的制备方法制备的核苷类似物,在体内具有长的生理半衰期和高的血清稳定性,作为一种放射性药物组合物,有助于肿瘤增殖诊断或治疗预后评估的发展,并进一步帮助观察药物的长期体内代谢。